Table 2.

Mean (SD) percentage changes in lipid parameters from baseline to week 8 by atorvastatin dose assignment in children and adolescents with heterozygous familial hypercholesterolemia

Variable	Tanner stage 1			Tanner stage ≥2
	Patients who stayed at 5 mg (n = 5)	Patients who increased to 10 mg (n = 10)	All patients (n = 15)	Patients who stayed at 10 mg (n = 9)	Patients who increased to 20 mg (n = 15)	All patients (n = 24)
Low density lipoprotein cholesterol (mmol/l)
Baseline mean	4.87 ± 0.48	6.37 ± 1.10	5.87 ± 1.18	5.11 ± 0.65	6.23 ± 1.00	5.81 ± 1.03
End point mean	3.06 ± 0.54	3.66 ± 0.80	3.46 ± 0.76	3.12 ± 0.40	3.63 ± 0.43	3.44 ± 0.48
% Change from baseline	−36.78 ± 11.16	−42.70 ± 6.45	−40.72 ± 8.41	−38.45 ± 7.84	−40.39 ± 11.71	−39.66 ± 10.28
Total cholesterol (mmol/l)
Baseline mean	6.76 ± 0.46	8.58 ± 1.06	7.97 ± 1.25	6.92 ± 0.71	8.40 ± 1.10	7.84 ± 1.20
End point mean	4.87 ± 0.39	5.39 ± 0.75	5.21 ± 0.69	4.66 ± 0.65	5.18 ± 0.49	4.99 ± 0.60
% Change from baseline	−27.80 ± 5.56	−37.17 ± 5.28	−34.05 ± 6.90	−32.43 ± 8.53	−37.45 ± 9.89	−35.57 ± 9.54
Triglycerides (mmol/l)
Baseline mean	0.76 ± 0.15	0.95 ± 0.27	0.89 ± 0.25	1.03 ± 0.37	1.20 ± 0.50	1.14 ± 0.46
End point mean, mmol/L	0.79 ± 0.34	0.79 ± 0.23	0.79 ± 0.26	0.72 ± 0.24	0.92 ± 0.42	0.84 ± 0.37
% Change from baseline	1.69 ± 31.48	−9.88 ± 33.31	−6.02 ± 32.06	−20.94 ± 39.24	−21.11 ± 23.85	−21.05 ± 29.69
High density lipoprotein cholesterol (mmol/l)
Baseline mean	1.35 ± 0.12	1.45 ± 0.29	1.41 ± 0.25	1.17 ± 0.18	1.18 ± 0.23	1.18 ± 0.21
End point mean	1.39 ± 0.31	1.38 ± 0.21	1.38 ± 0.24	1.24 ± 0.34	1.11 ± 0.23	1.16 ± 0.28
% Change from baseline	2.50 ± 15.02	−2.84 ± 14.49	−1.06 ± 14.36	5.99 ± 21.02	−5.19 ± 17.76	−1.00 ± 19.40
Very low density lipoprotein cholesterol (mmol/l)
Baseline mean	0.54 ± 0.15	0.76 ± 0.30	0.69 ± 0.27	0.65 ± 0.11	0.99 ± 0.31	0.86 ± 0.30
End point mean	0.42 ± 0.20	0.35 ± 0.15	0.37 ± 0.16	0.30 ± 0.12	0.44 ± 0.21	0.39 ± 0.19
% Change from baseline	−12.31 ± 57.38	−50.29 ± 21.44	−37.63 ± 39.75	−53.61 ± 19.21	−52.38 ± 29.34	−52.84 ± 25.55
Apolipoprotein A-I (g/l)
Baseline mean	1.42 ± 0.20	1.45 ± 0.20	1.44 ± 0.19	1.29 ± 0.20	1.24 ± 0.15	1.26 ± 0.17
End point mean	1.40 ± 0.14	1.40 ± 0.20	1.40 ± 0.18	1.24 ± 0.25	1.17 ± 0.22	1.20 ± 0.23
% Change from baseline	−1.24 ± 8.49	−3.37 ± 9.35	−2.66 ± 8.82	−2.60 ± 20.22	−4.82 ± 16.13	−3.98 ± 17.37
Apolipoprotein B (g/l)
Baseline mean	1.09 ± 0.13	1.49 ± 0.24	1.35 ± 0.28	1.26 ± 0.14	1.52 ± 0.18	1.42 ± 0.21
End point mean	0.79 ± 0.12	0.90 ± 0.15	0.86 ± 0.15	0.85 ± 0.10	1.04 ± 0.26	0.97 ± 0.23
% Change from baseline	−27.39 ± 5.97	−39.59 ± 5.83	−35.52 ± 8.22	−31.94 ± 11.64	−31.26 ± 18.57	−31.51 ± 16.04
Low density lipoprotein cholesterol/high-density lipoprotein-cholesterol
Baseline mean	3.63 ± 0.39	4.63 ± 1.69	4.30 ± 1.46	4.46 ± 0.79	5.41 ± 1.11	5.05 ± 1.09
End point mean	2.33 ± 0.72	2.70 ± 0.77	2.58 ± 0.75	2.63 ± 0.56	3.44 ± 0.87	3.13 ± 0.85
% Change from baseline	−36.49 ± 16.48	−39.95 ± 11.02	−38.80 ± 12.59	−40.82 ± 8.88	−35.84 ± 12.54	−37.71 ± 11.37